Global economic surplus of PCV

Project Details

Pneumococcal conjugate vaccine (PCV) remains one of the most expensive and underused vaccines two decades after its first market approval. The project aims to estimate the global economic surplus generated from the development and use of PCV globally and across country-income groups and manufacturers, and to explore the effect of alternative pricing strategies based on cross-subsidizing, pooled procurement, and various tiering mechanisms to assess the effect on the distribution of economic surplus across country income groups and manufacturers. Evidence from this project could inform the global policymaking intended to reduce inequalities in gains from vaccinations.

Project Duration

2022–2024

Researchers

• Fulgence Niyibitegeka (Project Lead)
• A/Prof Natalie Carvalho

Research Publications

Niyibitegeka F, Russell FM, Jit M, Carvalho N. Inequitable Distribution of Global Economic Benefits from Pneumococcal Conjugate Vaccination. Vaccines. 2024;12(7):767. https://doi.org/10.3390/vaccines12070767